Form D · Biotechnology
ClearDynamic Inc.
Halifax, A5 · CIK 0002099643
Offering snapshot reported Dec 11, 2025 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 5, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 11, 2025 | Initial | $1,999,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-566485
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Not Applicable | None |
Source: Form D, filed Dec 11, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Abraham | Director |
| Roar Askheim | Director, Executive |
| Andrew Bishop | Director |
| Daniel Boyd | Director, Executive |
| Carl Deirmengian | Director |
| Mark Foster | Director |
| William Hagaman Jr. | Director |
| Robin Phillips | Director |
| Stephanie Turner Cahill | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1344 Summer Street, Suite 212
Halifax, A5, B3H 0A8
Halifax, A5, B3H 0A8